Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2007-08-11
2008-12-09
Badio, Barbara P (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
07462610
ABSTRACT:
The instant invention provides potent antiandrogen compounds, such as 3β-acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in the prevention and treatment of biological conditions mediated by androgen receptors. Thus, for example, compounds of the invention are useful in the prevention and treatment of prostrate cancer. Furthermore, it has been discovered that compounds of the invention are useful in the prevention and treatment of androgen-independent cancers such as androgen-independent prostrate cancer. Finally, inventive compounds may be used to treat antiandrogen induced withdrawal syndrome.
REFERENCES:
patent: 3067216 (1962-12-01), Batres et al.
patent: 3127428 (1964-03-01), Tanabe et al.
patent: 3127430 (1964-03-01), Shapiro et al.
patent: 3221033 (1965-11-01), Shapiro et al.
patent: 3332967 (1967-07-01), Oliveto et al.
patent: 4898694 (1990-02-01), Schwartz et al.
patent: 5157031 (1992-10-01), Schwartz et al.
patent: 5292730 (1994-03-01), Lardy
patent: 5296481 (1994-03-01), Partridge et al.
patent: 5387583 (1995-02-01), Loria
patent: 5424463 (1995-06-01), Lardy et al.
patent: 5506223 (1996-04-01), Lardy et al.
patent: 5585371 (1996-12-01), Lardy
patent: 5686438 (1997-11-01), Daynes et al.
patent: 5744462 (1998-04-01), Schwartz et al.
patent: 5763433 (1998-06-01), Morfin
patent: 5859000 (1999-01-01), Dowell et al.
patent: 5912240 (1999-06-01), Loria
patent: 6667299 (2003-12-01), Ahlem et al.
patent: 2003/0083231 (2003-05-01), Ahlem et al.
patent: 2004/0043973 (2004-03-01), Ahlem et al.
patent: 2004/0097406 (2004-05-01), Ahlem et al.
patent: 2004/0116359 (2004-06-01), Ahlem et al.
patent: 2004/0220114 (2004-11-01), Ahlem et al.
patent: 2004/0242618 (2004-12-01), Lardy et al.
patent: 2005/0159366 (2005-07-01), Ahlem et al.
patent: 2005/0256095 (2005-11-01), Ahlem et al.
patent: 2005/0282732 (2005-12-01), Ahlem et al.
patent: 2006/0063749 (2006-03-01), Ahlem et al.
patent: 2006/0073099 (2006-04-01), Frincke et al.
patent: 2006/0079492 (2006-04-01), Ahlem et al.
patent: 2006/0088473 (2006-04-01), Dowding et al.
patent: 2007/0014719 (2007-01-01), Reading et al.
patent: 2007/0077201 (2007-04-01), Reading et al.
patent: 2007/0129282 (2007-06-01), Ahlem et al.
patent: 2008/0004250 (2008-01-01), Lardy et al.
patent: 2008/0070881 (2008-03-01), Lardy et al.
patent: 250537 (1987-10-01), None
patent: 50-40553 (1973-05-01), None
patent: 52-71456 (1977-06-01), None
patent: WO01/23405 (2001-04-01), None
patent: WO02/069977 (2002-09-01), None
patent: WO2004/089304 (2004-10-01), None
Cadot, et al. “First synthesis of a steroid containing an unstable 19-nor-androsta-1,5-dien-3-one system”Tetrahedron(2006) 62: 4384-4392.
Nussbaum, et al. Double bond isomerization of steroids A-ring α,β-unsaturated ketones: 1,5-dien-3-onesJ. Amer. Chem. Soc. 1959 81: 4574-4577.
Chang, et al Suppression of a Δ5-adrostenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cellsProc. Natl. Acad. Sci. USA, 1999, 96:11173-111777.
Fink, et al Peripheral serum corticosteroid concentrations in relation to the rat adrenal cortical circadian rhythm in androgen-induced hypertension,Hypertension1980, 2:617-622.
Gaunt, et al. Antagonists to cortisone: an ACTH-like action of steroids,Endocrinol. 1953, 52:407-423.
Kaneko, et al. Hydroboration of steroidal-1,5-dien-3β-ols: A general procedure for the introduction of a hydroxy group at 1α-poition of the 3-oxygenated steroids,Chem. Pharm. Bull. (Jpn), 1974, 22(9):2101-2107.
Kaneko, et al. 1α-hydroxylation of cholesterol and related 3-hydroxysteroids,Tet. Lett. 1973, (23):2339-2342.
Kroboth, et al DHEA and DHEA-S: A review,J. Clin. Pharm. 1999, 39:327-348.
Lardy, et al., Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone,Steroids, 1998, 63:158-165.
Marwah, et al, C19-Steroids as androgen receptor modulators: Design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonists,Bioorg. Med. Chem., 2006, 14:5933-5947.
Miyamoto, et al., Δ5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells,Proc. Natl. Acad. Sci. U. S A. 1998, 95(19):11083-11088.
Miyamoto, et al.,3β-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity,Proc. Natl. Acad. Sci. USA, 2003, 100:4440-4444.
Miyamoto, et al., Identification of steroid derivatives that function as potent antiandrogensInt. J. Cancer2005, 117:866-872.
Schubert, K et al Stereospecific hydrogenation of Δ4-, Δ1,4-, Δ4,6- and Δ1,4,6-3-ketosteroids byClostridium Parapurificium, Steroids Suppl.1, 1965, pp. 175-184.
Shapiro, et al. Deconjugation of Δ1,4-3-Ketosteroids, Steroids 1964 3(2), pp. 183-188.
Shapiro, et al. 3β-Hydroxy-1,5-bis-dehydro steroids,Steroids1966, 8(4):461-93.
Shibata, et. al, Further preparation of steroidal diosphenols. II. Synthesis of 2,16α, 17β- and 2,16β, 17β-trihydroxy-4,4-dimethylandrosta-1,5-dien-3-ones,Chem. Pharm. Bull. (Jpn), 1967, 15:186-193.
Tummala, et al Correlation between the administrated dose of DHEA and serum levels of DHEA and DHEA-S in human volunteersClin. Biochem. 1999, 32:355-361.
Lardy Henry A.
Marwah Ashok
Marwah Padma
Badio Barbara P
Hollis-Eden Pharmaceuticals, Inc.
Muenchau Daryl
LandOfFree
Prostate cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostate cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostate cancer treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4046930